36 results about "Interstitial tissue" patented technology

An autonomous active medical implantable device, with a power supply and a wake-up circuit that responds to receipt of specific pulses transmitted through the interstitial tissues of the body transmitter device (40) generates trains of modulated pulses applied to electrodes (22, 24), and a receiver (50) processes (e.g., filter, amplify and demodulate) pulses collected on electrodes (22′, 24′). The receiver circuits (50) are selectively activated from a dormant (sleep) state in which they are not powered by a power source (34), to an operational (active) state in which they are powered and able to process (e.g., filter, amplify and demodulate) the collected pulses specific wake-up pulse train, configured in a predetermined characteristic pulse pattern triggers passive wake-up circuits (66) in the receiver (50) to switch the receiver circuits from the sleep state to the operational state.

A reinforced arthroscope comprising external ribs to provide for a number of separate fluid channels, such as inflow, outflow and interstitial tissue drainage, when the arthroscope is slipped into a disposable external sheath. The arthroscope is constructed to be sufficiently rigid so as to penetrate and move within a joint without damaging the rod optics inside. The externality of the arthroscope channels allow for cleaning and sterilizing the scope between uses.

The present invention relates to multipotent stem cells derived from the interstitial tissues of skeletal muscle. The multipotent stem cell of the present invention is capable of differentiating into skeletal muscle cells, smooth muscle cells, cardiomyocytes, blood cells, vascular endothelial cells, adipocytes, osteoblasts, nervous cells, hepatocytes and pancreatic cells, and is useful for regeneration of tissues and cells and treatment for cardiac failure, hepatic insufficiency, renal insufficiency, leukemia, nerve degeneration disease, arthritis, diabetes, arteriosclerosis, and the like.

A device for preventing the start-up or initial operation of a vehicle, in particular of a motor vehicle, by a vehicle driver who is under the influence of alcohol, as well as a vehicle equipped with such a device. The device includes a device for determining the alcohol content in the breath, blood, tissue, sweat of the skin, or in the interstitial tissue fluid of the vehicle driver, as well as an immobilizer which prevents the start-up or the initial operation of the vehicle when the alcohol content in the vehicle driver's breath, blood, tissue, sweat of the skin, or interstitial tissue fluid, that is ascertained by the device, exceeds a specified threshold value. Means are provided for bypassing or disabling the immobilizer.

The invention relates to a separation and storage method of a pouch fat interstitial cell, which comprises the following steps of: cutting to obtain a pouch fat tissue by adopting a surgical knife, extracting an interstitial tissue of the pouch fat tissue and separating the cell by using an adherent method. The culture and amplification method of the pouch fat interstitial cell comprises the following steps of: carrying out large-scale tissue culture by adopting a paper carrier technology, freezing and storing by using a definite and non-specific genetic component and preserving the cell for a long time. Through the separation and storage method, the pouch interstitial cell can be extracted, massively cultured and preserved for a long time; and the cultured interstitial cell can be used for promoting the healing of skin wound, the healing of diabetic ulcer, the repair of myocardial injury and the repair of hepatic injury.

The esophageal cancer pathological image labeling method comprises the following steps: a) performing dyeing correction processing on an esophageal pathological image subjected to H & E dyeing; b) labeling expert canceration areas; c) mapping the canceration area outline marked by the expert into a pathological image of 40X; d) constructing an epithelial tissue contour detection model; d-1) marking whether pixel points belong to an epithelial region, an interstitial tissue or an irrelevant blank region; (d-2) constructing an end-to-end convolutional neural network model; and e) fusing the labeling areas. According to the method, the epithelial tissue contour is automatically drawn in the labeling process according to the characteristic that the esophageal cancer morbidity area occurs in the epithelial tissue basal layer area, so that the time cost of expert labeling is greatly saved. The method only aims at esophageal pathological section image modeling; only the edge of the epithelialtissue is detected, the model is relatively simple, operation is rapid, epithelial boundary detection has obvious advantages in detection precision, meanwhile, the method automatically learns effective features and expressions, the complex manual feature selection process is avoided, and the actual application requirements can be met.

Methods for detecting the presence of atherosclerotic structures in order to diagnose or prevent atherosclerosis are provided herein. In particular, it has been found that methylene blue injected intravenously acts as an excellent indicator because the compound targets high-risk plaque, atheroma, macrophages, and other atherosclerotic structures formed within the endothelial walls of a vessel of a subject. Because the compound provides a unique binding profile with uptake only in plaque or atheroma, and not the normal or healthy vascular interstitial tissue, methylene blue maintains a good plaque-to-background ratio for imaging purposes. This enables healthcare providers to determine the status of atherosclerosis development in vivo within a patient with higher certainty and at lower costs. The disclosed methods allow for high-resolution mapping of plaque build-up, plaque pathobiology, and other atherosclerotic structures within a vessel of a subject by using methylene blue as an imaging agent.

The invention discloses a colorectal cancer pathological image prognosis auxiliary prediction method and system. The method comprises the following steps: a background separation step: dividing into a background region and a tissue region; an image small block segmentation step: carrying out image small block segmentation on the tissue region according to a preset pixel size; a depth feature extraction step: extracting features of the segmented small image blocks based on a convolutional layer and a pooling layer of a colorectal cancer survival time prediction model to obtain features of the small image blocks, and encoding the small image blocks into a one-dimensional array form after processing of the convolutional layer; a clustering step: clustering the features of the small blocks of the image based on K-means clustering, and dividing tumor epithelial tissues, interstitial tissues, mucus, normal tissues and necrotic parts; and a risk division step: dividing a risk range. According to the invention, the image small blocks of the whole pathological image are automatically classified through K-means clustering, and then different types of image small blocks are selected for joint training, so that the survival time prediction of the prognostic patient of the colorectal cancer patient is more accurate.

Myocardial hypertrophy is a pathological change of a plurality of kinds of angiocardiopathy. The main mode is the heart remodeling comprising cardiac muscle cell hypertrophy and change of the interstitial tissue component mainly. In the present invention, the nitrate medicine is used in treatment for myocardial hypertrophy caused by various reasons and excellent therapy effect is obtained. Currently the nitrate medicine is extensively applied in treatment for the coronary heart disease, the heart colicky pain and heart failure. Preload of the heart and myocardial consumption of oxygen are reduced by extension of the venous system. The drugs used in clinical field currently comprise Nitroglycerin, Amyl Nitrite, dicho nitric acid sorbite, sorbide dinitrate, 5-isosorbide dinitrate, Nitroglycerin, pentanitrol ters and itramine tosylate.

The present invention relates to an implant attachment stabilizer having, as an effective component, a methanebisphosphonic acid derivative represented by general formula (I)[where, in the formula, X, Y, m, n, <CUSTOM-CHARACTER FILE="US06692758-20040217-P00900.TIF" ALT="custom character" HE="20" WI="20" ID="CUSTOM-CHARACTER-00001"/>, A, B, R<1>, R<2>, R<3 >and R<4 >are as defined in the Specification], or hydrate thereof.The methanebisphosphonic acid derivatives represented by general formula (I) or the hydrates thereof, to which the present invention relates, have an interstitial tissue proliferation inhibiting action and an osteolytic factor production inhibiting action and, in particular, since they inhibit osteolysis through the inhibition of the interstitial tissue proliferation which accompanies implant attachment and the inhibition of osteolysis factor production at the implant periphery, they are effective in the prevention of implant loosening and detachment, and it is possible to extend the implant attachment period in the case of implants such as artificial joints, and implants in the oro-dental field.

Identification of the true nature and metabolic action of 3-methyleneoxindole (MO), a naturally occurring catabolite of the plant auxin, indole-3-acetic acid (IAA). Description of the two novel methods of synthesis of MO which produce the pure, biologically active auxin compound of MO. Discovery and description of the causes for the erroneous classification of MO as an inert compound with no auxin activity. These findings and methods of synthesis correct the ubiquitous theoretical errors which have driven scientific investigation and plant science research of plant auxins for nearly forty years. Researchers have failed to observe the auxin activity of MO because of the use of standard but incorrect synthetic techniques which have consistently produced impure forms of 3-bromooxindole-3-acetic acid (3-Brox), the synthetic precursor of MO. In addition, the use of dimethylsulfooxide as a solvent for MO has been identified as a major source of contamination of MO during synthesis. This invention describes two novel methods for synthesizing (MO). By using purified MO and avoiding the use of dimethylsulfoxide, it was found that the resulting MO product to be 100 to 1,00 fold more effective than IAA in promoting rooting in plant cuttings; supporting tissue differentiation and growth in stage I, stage II and stage III media used for the micropropagation of explants; promoting the formation of callus tissue over wounded plant parts; and, stimulating the production of interstitial tissue between scion and rootstock to increase the success rate for grafting. Therefore, this invention identifies MO as the dominant auxin in shoot acceleration, root development, wound sealing and scion acceptance. Finally, the correct pathway from IAA to MO is presented.

ACE receptors are affected in severe acute respiratory distress syndrome related coronaviruses. ACE genes are directly related to the morbidity and mortality of those with cystic fibrosis. The thick, sticky mucus in the respiratory, and digestive systems, is seen in the inherited disease cystic fibrosis. Viral induced sticky mucus in the respiratory and digestive systems can also be appreciated as a response to viral pathogens where the cycle of mucus production in vivo induces the recruitment of more mucus production to the extent that cellular damage occurs within the lower respiratory track requiring intubation as a life saving measure. In the most severe cases mechanical intubation fails due to the fact that no control over the recruitment of mucus production was achieved at the onset. SARS pathology shows inflammatory exudation in the alveoli and interstitial tissue, with hyperplasia of fibrous tissue and fibrosis. Inherited cystic fibrosis pathology shows atelectasis, mucoid impaction, acute and chronic inflammation, bronchiectasis, cyst formation, and fibrosis widespread. A virally induced disorder in relations to ACE2 receptors can be treated successfully at the early onset with inherited cystic fibrosis disease mimicking techniques with the efforts of minimizing the activity and utilization of the ACE2 receptor. Cystic fibrosis lung infections, and opportunistic pathogens contribute to chronic airway inflammation that is characterized by neutrophil/macrophage infiltration, cytokine release and ceramide accumulation. In terms of virally induced forms off ACE2 receptor pathologies, as it related to coronavirus such as Covid 19, presumably ceramide precursors which aid in intracellular transport of the virus into the cell via inflammation and remodeling is present in alveolar tissues of the lung in patients with cystic fibrosis while the same pathology occurs in patients with virally induced forms of ACE2 pathology which to often progresses to SARS or ARDS.

The invention discloses a burn wound tissue activity evaluation system based on a fluorescence development image, and relates to the technical field of burn wound evaluation, the burn wound tissue activity evaluation system comprises a fluorescence development acquisition module, a development image processing module and a tissue activity evaluation module, the fluorescence development acquisition module is used for performing fluorescence development on a burn wound and acquiring a development image; the developing image processing module is used for obtaining fluorescence intensity change data of the anchoring pixel sites according to the fluorescence developing time sequence, and obtaining a statistical value of each anchoring pixel site according to the fluorescence intensity change data; and the tissue activity evaluation module is used for evaluating the tissue activity of each anchoring pixel site according to the statistical value. According to the method, the solidification area, the stasis area and the hyperemia area of the burn wound surface are distinguished through the peak value and the slope of the fluorescence intensity curve, so that necrotic tissues and interstitial tissues of the wound surface are accurately identified, and the accuracy of deep diagnosis of the burn wound surface is improved.

The invention discloses a method for effectively treating varicocele by morida officinalis polysaccharide extracts through inhibiting testis blood vessel generation. The method comprises the followingsteps of (1) building an experimental varicocele animal model; (2) extracting morida officinalis coarse polysaccharide; performing primary purification; then, studying and discussing the restorationeffect of the morida officinalis coarse polysaccharide on the experimental varicocele rat hypothalamus-pituitary gland-testis axis, particularly the restoration effect in the early stage and developing stage of the disease; (3) obtaining a result showing that 100mg/kg of morida officinalis coarse polysaccharide can restore the double-side testis sperm production function and epididymal sperm quality in the early stage of the varicocele; the mechanism can be relevant to the angiogenesis inhibition and interstitial tissue normal metabolism maintenance. The sperm production function of a subclinical or varicocele early-stage patient can be improved; the progressive lesion of the testis interstitial tissue and blood vessels can be inhibited.

The invention provides a cataplasm with an effect of treating bronchial asthma as well as a preparation process and an application thereof. The cataplasm is prepared from the following raw medicinal materials in parts by weight: 1.5-2.5 parts of white mustard seed, 1.5-2.5 parts of rhizoma corydalis, 0.5-1.5 parts of manchurian wildginger herb, 0.5-1.5 parts of raw gansui root, 0.5-1.5 parts of ephedra, 0.5-1.5 parts of semen lepidii, 0.5-1.5 parts of cassia bark, 0.5-1.5 parts of flos caryophyllata and 0.5-1.5 parts of fructus gleditsiae. The preparation process comprises the following steps: screening the raw medicinal materials with an 80-mesh sieve respectively, and mixing the screened raw medicinal materials uniformly according to parts by weight; adding aluminum dihydroxy glycinate and EDTA (Ethylene Diamine Tetraacetic Acid) into a beaker containing glycerol, then adding NP-700, and mixing the materials uniformly as a phase A; dissolving PVP K90 and tartaric acid in distilled water, adding prepared medicine powder, and mixing the materials uniformly as a phase B; and adding the phase B into the phase A, mixing uniformly, then pouring the mixture onto non-woven cloth, covering the non-woven cloth with an anti-sticking layer, flattening the non-woven cloth, drying the flattened non-woven cloth in a drying box of 60 DEG C for 1 hour, then taking the dried non-woven cloth out, and performing cutting to obtain the cataplasm. The cataplasm provided by the invention can achieve an aim of treating the bronchial asthma in a remission period and preventing relapse of asthma by relieving inflammatory cellular infiltration in pulmonary interstitial tissues and reducing the broadening degree of the pulmonary interstitial tissues.